Hugel said Tuesday that its consolidated operating profit for last year rose 21.3% from a year earlier to 201.6 billion won. Revenue increased 14% to 425.1 billion won, and net profit edged up 0.6% to 144.0 billion won, based on preliminary results. The company said it was the best performance in its history.
Hugel said results were driven by strong global sales of its botulinum toxin product Botulax and its hyaluronic acid fillers The Chaeum and Byryzn, along with rapid growth in its cosmetics brands Wellage and Byryzn BR.
By product, toxin revenue rose 15% to 233.8 billion won, while filler sales increased 1.7% to 129.7 billion won. Cosmetics and other products climbed 45.9% to 61.6 billion won. Combined annual sales of toxin and fillers rose 10% to 363.5 billion won, including overseas sales up 22% to 268.5 billion won. The export share for the two products expanded to 74% in 2025 from 66% in 2024.
Growth was strongest in North and South America, including the United States and Brazil. Combined toxin and filler sales in the region jumped 105% to 67.9 billion won, and fourth-quarter revenue surged 310% from a year earlier to 29.2 billion won.
Carrie Strom, Hugel’s global CEO, said the company posted sales in the 400 billion won range for the first time, citing “solid global competitiveness.” She said Hugel plans this year to strengthen its mid- to long-term growth base in key markets including the United States, China, Europe and Brazil.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.